ADAM BLAKEMAN: Open Payments
NPI 1275071128 · RIGBY, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 37 payments from 16 companies in 2025. Trend: 2023 $518 · 2024 $1,006 · 2025 $661
Food & beverage: $661
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $158 |
| Lilly USA, LLC | 6 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Astellas Pharma US Inc | 1 | $34 |
| PFIZER INC. | 2 | $32 |
| Insulet Corporation | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
Products named: MOUNJARO, VRAYLAR, FANAPT, Auvelity, UBRELVY, CAPLYTA, XIFAXAN, Veozah.
Industry payments across ID — which companies pay providers there.
